SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today introduced three new microarrays to meet the needs of cytogenetic laboratories conducting both prenatal and postnatal ...

Use of Agilent’s custom microarrays in the SOMAscan® assay will help drive biomarker discovery efforts as well as novel diagnostics and accelerated pharmaceutical development SANTA CLARA, Calif. & ...

PALO ALTO, Calif., Jan. 5, 2005 -- Agilent Technologies Inc. (NYSE: A) today announced a breakthrough development that enables the rapid advance of microarray-based comparative genomic studies in ...

OXFORD, England--(BUSINESS WIRE)-- Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch® 3D ...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced that the United States-Latin American Cancer Research Network (US-LACRN) has selected Agilent Gene Expression ...

Roche and Agilent Technologies, Inc. announced the signing of an exclusive agreement to provide continued service to NimbleGen microarray customers as Roche phases-out its NimbleGen array production ...

Agilent’s Microarray Hybridization Oven was designed for optimal hybridization performance and ultimately, consistently reliable data. With advanced features including variable and adjustable ...

Due to its higher resolution, oligo array CGH has recently made strong inroads in the cytogenetic lab. It’s not surprising. With an increased sensitivity of more than 1,000-fold, microarrays can ...

Agilent Technologies Inc. has announced the extension of its technology access program to National Cancer Institute (NCI) extramural researchers. The NCI funds approximately 4,500 research grants a ...

The DNA microarray market is witnessing steady growth due to the rising demand for advanced genomic research, personalized medicine, and early disease diagnosis. The increasing prevalence of cancer, ...